MARK2 and neoplasm: It reduces tumor cell growth and progression through inhibition of multiple serine/threonine kinases involved in tumor progression and angiogenesis.5 These include the vascular endothelial growth factor receptor (VEGFR-2/3), platelet-derived growth factor receptor (PDGF-R), Flt3, c-Kit, and Raf kinase.5,6